Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Candel announced financial results for quarter ended March 31, 2026.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Candel announced financial results for quarter ended March 31, 2026
- Full results and management commentary available in furnished Exhibit 99.1
- Disclosure furnished under Regulation FD, limiting Section 18 Exchange Act liability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.